CNS Pharmaceuticals (CNSP) to Release Quarterly Earnings on Wednesday

CNS Pharmaceuticals (NASDAQ:CNSP) will likely be announcing its results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($5.09) per share for the quarter.

CNS Pharmaceuticals Trading Down 2.5%

NASDAQ:CNSP opened at $3.13 on Tuesday. The company has a market cap of $1.94 million, a P/E ratio of -0.10 and a beta of 2.70. CNS Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $55.20. The company’s 50-day moving average price is $5.45 and its 200-day moving average price is $6.77.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, CNS Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $20.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Boothbay Fund Management LLC purchased a new position in CNS Pharmaceuticals in the fourth quarter worth approximately $71,000. Ikarian Capital LLC acquired a new position in shares of CNS Pharmaceuticals in the 4th quarter valued at $241,000. Finally, Armistice Capital LLC purchased a new position in shares of CNS Pharmaceuticals during the 2nd quarter worth $335,000. 14.02% of the stock is currently owned by institutional investors and hedge funds.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.